BioStock Intestor Pitch with Moberg Pharma
| Published June 12, 2024

BioStock Investor Pitch: Moberg Pharma

After many years of work, Moberg Pharma has now reached the market with its nail fungus treatment. How has the over-the-counter drug Terclara been received in Sweden? CEO Anna Ljung has visited BioStock's studio to discuss the launch and present plans to become a global leader in nail fungus.

See her presentation in the BioStock Investor Pitch below.

BioStock is a news service and does not provide investment advice, does not mediate any investment orders and does not take any responsibility for actions and/or any loss or damage of any kind based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor. The content of BioStock's news and analyses is independent, but as BioStock's operations are partly financed by companies in the industry, the BioStock website may contain news about companies from which BioStock has received funding.

This material has been prepared for marketing purposes and is not and should not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a prospects which has been announced and published on the above-mentioned company's website.